COR Therapeutics ( CORR) posted a first-quarter loss of 5 cents a share, a penny better than analysts had expected. In the year-earlier period, the biotech posted a loss of 19 cents a share. Revenue climbed 27% to $22.8 million from $17.9 million. The company also again said it expects to earn 35 cents to 37 cents a share this year. Analysts expect that it'll earn 34 cents a share, according to Thomson Financial/First Call.